Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, small cell
Stage/Subtype:  extensive stage small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 41 for your search:
Start Over
Whole-Brain Radiation Therapy with or without Hippocampal Avoidance in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-CC003, NCI-2015-01548, NCT02635009
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO30081, NCI-2016-01683, 2015-004861-97, NCT02763579
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-604, NCI-2017-00791, 2016-004309-15, NCT03066778
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9525, NCI-2014-00461, 13-505, NCT02079740
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: G1T28-02, NCI-2015-01360, 2016-001583-11, NCT02499770
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: G1T28-03, NCI-2015-01365, 2016-004611-13, NCT02514447
Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-1380, NCI-2016-01991, NCT02748889
Ipilimumab, Nivolumab, and Thoracic Radiation Therapy in Treating Patients with Extensive-Stage Small Cell Lung Cancer after Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18914, NCI-2017-00285, NCT03043599
Trametinib and Erlotinib Hydrochloride in Treating Patients with Stage IV or Recurrent Lung Cancer with EGFR Activating Mutation
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 15-098, NCI-2017-00542, NCT03076164
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IT-01, NCI-2017-01040, NCT03058289
Cisplatin or Carboplatin and Etoposide With or Without Vandetanib in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer or High-Grade or Poorly Undifferentiated Neuroendocrine Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LUN06-113, NCI-2013-00309, 0712-21, 1011004344, IRUSZACT0083, NCT00613626
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Stereotactic Body Radiation Therapy, Radiofrequency Ablation, and Microwave Ablation in Treating Patients with Inoperable and Recurrent Lung Cancer Near Central Airways
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-08-026, NCI-2010-01669, 10-000656, JCCC-SUPPL-3, SBRT-RFA Lung, NCT01051037
Ponatinib Hydrochloride in Treating Patients with Stage III-IV Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2002, NCI-2013-01644, PAM004-1, PAM005-2, NCT01935336
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: M14-361, NCI-2015-00490, 2014-001764-35, NCT02289690
Pegylated Irinotecan NKTR 102 in Treating Patients with Refractory Brain Metastasis from Non-small Cell Lung Cancer or Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LUN0067, NCI-2014-02101, 350, 351, NCT02312622
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Trastuzumab Emtansine in Treating Patients with HER2 Amplified or Mutant Advanced Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-335, NCI-2016-00262, NCT02675829
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients with Small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9974, NCI-2016-01363, TBD, NCT02899728
RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-211-01, NCI-2016-01889, NCT02489903
Pembrolizumab in Treating Patients with Extensive-Stage Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: S16-01031, NCI-2017-00123, NCT02934503
Start Over